Plenary V: HLA-Peptide Targeting and Personalized Medicine

Speaker(s)

• 

  Richard Carvajal, MD

  Professor of Medicine
  Northwell Health Cancer Institute
  Lake Success, NY
• 

  Aude Chapuis, MD

  Associate Professor
  Fred Hutch Cancer Center
  Seattle, Washington

Moderator(s)

• 

  Zachary Antovich, BS

  President
  Skywood Biosciences, Inc
  Woodside, CA
• 

  Michiko Taniguchi, PhD, F(ACHI)

  Assistant Professor/Associate Director of HLA Laboratory
  Washington University in St. Louis
  Saint Louis, Missouri

This session will explore recent clinical breakthroughs in immunotherapy that target tumor-associated antigens presented by HLA molecules on the cell surface. Speakers will highlight newly approved therapies alongside translational strategies and emerging clinical data shaping the future of precision oncology.

This session will explore recent clinical breakthroughs in immunotherapy that target tumor-associated antigens presented by HLA molecules on the cell surface. Speakers will highlight newly approved therapies alongside translational strategies and emerging clinical data shaping the future of precision oncology.

Presentations:

• 9:30 AM - 10:00 AM US EDT

  T Cell Redirection in Uveal Melanoma: A New Therapeutic Modality for the Treatment of Solid Tumors
  

  Speaker: Richard Carvajal, MD – Northwell Health Cancer Institute
• 10:00 AM - 10:30 AM US EDT

  Overcoming the Barriers of Transgenic T-cell Receptor- based Therapy
  

  Speaker: Aude Chapuis, MD – Fred Hutch Cancer Center